Olmesartan not checked

Autotelicbio

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
1 active
2 in total · 1 in the EU
Targets
—
None known yet

What this is

How it works
Blocks the effect of angiotensin II, a hormone that narrows blood vessels. Lowers blood pressure.-sartan: angiotensin II receptor antagonists WHO name stem
How it’s given
“First stage: ATB-1011 for 5days, repeated administration, Second stage: ATB-1012 + ATB-1011 for 5days, repeated administration”In the company’s words, NCT04856969 on ClinicalTrials.gov
Main trialPhase 1
“To evaluate the interaction between two investigational products by comparing and analyzing pharmacokinetic interactions and safety in steady state after multiple oral administration of ATB-1011 or ATB-1012 alone or in combination in healthy adult volunteers.”In the company’s words, NCT04856969 on ClinicalTrials.gov

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 1Completed 4 May 2021 Clinical Trial to Evaluate Pharmacokinetic Interaction of ATB-1011 and ATB-1012 in Healthy Adult Volunteers
Phase 4Authorised not given Pharmacological optimization in prevention in Heart Failure: A Sex-gap? (PopS-HF Trial)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Olmesartan

Following is part of Solo: you see every change to Olmesartan the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in